Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Point72 Asset Management and Array Biopharma Inc (ARRY)

Page 1 of 9

Array Biopharma Inc (NASDAQ:ARRY): Steve Cohen’s Point72 Asset Management filed an amended 13D.

You can check out Point72 Asset Management’s latest holdings and filings here.

Please follow Point72 Asset Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Point72 Asset Management or update its stock holdings.

Steve Cohen
Steve Cohen
Point72 Asset Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Point7 0 9,172,507 0 9,172,507 9,172,507 5.4%
Point7 0 9,172,507 0 9,172,507 9,172,507 5.4%
Cubist Systematic Strategies 0 21,611 0 21,611 21,611 Less%
Steven A. Cohen 0 9,194,118 0 9,194,118 9,194,118 5.4%
Steve Cohen
Steve Cohen
Point72 Asset Management

Page 1 of 9 – SEC Filing

Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. )*


(Name of Issuer)

Common Stock, Par Value $0.001 Per Share

(Title of Class of Securities)
(CUSIP Number)
September 11, 2017
(Date of Event which Requires Filing
of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Array Biopharma Inc (NASDAQ:ARRY)
Trade (NASDAQ:ARRY) Now!
Page 1 of 9